Sentence examples for specificity of population from inspiring English sources

The aim of the study is to find out a specificity of population aging process within the young geo-political construction at the northern edge of Europe entitled Barents Euro-Arctic Region (BEAR).

This might be due to the specificity of our population, made up of young, healthy workers, none of whom were over 55 years of age.

The rationale behind adaptation studies is that repetition of the same stimulus type results in response suppression which reveals neural populations that are tuned to the processing of a specific stimulus attribute, that is, repetition suppression reveals functional specificity of neural populations.

Third, our results could be influenced by the criteria adopted to assess readiness and to determine SBT success or failure, and we cannot exclude that the results may have been different by adopting additional criteria more adapted to the specificities of our population.

This hypothesis is based on the argument that, the local volunteer enumerators of citizen-led surveys are likely to be more sensitive to the specificities of local population distribution and (recent) changes than those centrally trained; and may be more effective at reaching hard-to reach groups such as those nomadic groups and those in urban slums.

The specificities of pediatric population make it difficult to launch clinical trials assessing efficacy of TTs in osteosarcomas.

Population specificity of genetic variants, if the population-specific allele is the derived allele, might originate from two different scenarios: in the first scenario, a variant allele originates in a single population and remains restricted to the population of its origin.

The SP was stained with Hoechst dye in the presence of the Ca++-channel blocker Verapamil hydrochloride to verify the specificity of the SP population.

However, the origin and specificity of the CD4+C25+ population generated by this or other helminth infections have yet to be delineated.

Unfortunately, the rarity of these pathologies and the specificity of the pediatric population don't hold pharma industries nor governments to delineate phase III trials and prove the benefit of such compounds for refractory osteosarcomas.

We used the SiMRiSC model (Greuter et al, 2010; Lu et al, 2012) based on Jacobi et al (2006) and extended the model by incorporating data on the specificity of screening, on population death rates and on associated costs.